Artan Bio was founded on a simple belief: that a specific, universal feature of aging can be addressed directly. As we enter a new chapter, that belief is what carries us forward.
That chapter begins with leadership. Brian Bodemann steps in as Chief Executive Officer, working alongside co-founders Michael Torres, our Chief Scientific Officer, and Anthony Schwartz, our Chief Operating Officer. Together they connect the platform’s biology to the indications, partners, and markets it can serve, and to the traditional capital that carries a program toward the clinic.
Our work stays focused. We build codon-suppressor therapies designed to restore full-length protein translation where a premature stop interrupts biology. One platform, one lead program, and a deliberate path toward the clinic.
We will keep sharing the story here: the why behind the science, the how of the platform, and the progress as we make it. The detail lives in our conversations with investors and partners, where it belongs.